Friday, 16 October 2026European Markets

TRIGANO Stock Was Up By 9.99% Before The Weekend

Loading stream...

(vianews) - the market ended the session with trigano (tri.pa) rising 9.99% to €163.00 on friday, after three sequential sessions in a row of gains. cac 40 rose 0.01% to €8,205.81, after three sequential sessions in a row of gains, on what was a somewhat up trend exchanging session today.

trigano's last close was €163.00, 6.12% higher than its 52-week high of €153.60.

about trigano

trigano s.a., together with its subsidiaries, designs, manufactures, markets, and sells leisure vehicles for individuals and professionals in europe. it offers camping cars, caravans, motorhomes, trailers, and outdoor habitats. the company also provides mobiles homes, spare parts, and accessories, as well as leisure financing services. it offers its products through dealer networks and distributors, as well as through its online sales site, triganostore.com. trigano s.a. was founded in 1935 and is based in paris, france.

earnings per share

as for profitability, trigano has a trailing twelve months eps of €15.95.

pe ratio

trigano has a trailing twelve months price to earnings ratio of 10.22. meaning, the purchaser of the share is investing €10.22 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 20.93%.

moving average

trigano's worth is way above its 50-day moving average of €145.83 and way above its 200-day moving average of €136.33.

revenue growth

year-on-year quarterly revenue growth grew by 11.2%, now sitting on 3.48b for the twelve trailing months.

volume

today's last reported volume for trigano is 123943 which is 616.76% above its average volume of 17292.

yearly top and bottom value

trigano's stock is valued at €163.00 at 21:36 est, above its 52-week high of €153.60.

more news about trigano (tri.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com